Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Coherus Biosciences ( (CHRS) ) is now available.
On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which included the UDENYCA, YUSIMRY, and CIMERLI franchises. This strategic shift led to the reclassification of these businesses as discontinued operations in their financial reports, reflecting a focus on their innovative oncology pipeline and the expansion of LOQTORZI sales.
The most recent analyst rating on (CHRS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.
Spark’s Take on CHRS Stock
According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.
Coherus Biosciences faces significant financial and valuation challenges, with declining revenues and a negative P/E ratio. Technical indicators suggest bearish momentum. However, the earnings call provided some positive insights into strategic initiatives and financial improvements, slightly offsetting the negative aspects.
To see Spark’s full report on CHRS stock, click here.
More about Coherus Biosciences
Coherus Biosciences is a fully integrated commercial-stage oncology company with a focus on innovative cancer treatments. The company has an approved PD-1 inhibitor, LOQTORZI, and is developing additional clinical candidates targeting various cancers such as liver, lung, and head and neck cancers.
Average Trading Volume: 1,285,744
Technical Sentiment Signal: Hold
Current Market Cap: $164.4M
Learn more about CHRS stock on TipRanks’ Stock Analysis page.